Spectranetics Receives CE Mark for TightRail™ Rotating Dilator Sheath Platform

Cardiac lead extraction device’s preliminary launch extends to Europe Colorado Springs, CO – May 22, 2014 – The Spectranetics Corporation today announced receipt of CE marking for the TightRail™ Rotating Dilator Sheath platform. The product combines unprecedented shaft flexibility and column strength to help physicians safely navigate the vasculature during cardiac lead extraction procedures. The announcement includes TightRail and a companion product: TightRail™ Mini Rotating Dilator Sheath. The Mini is designed to gain vascular access, dilating heavily fibrosed and calcified tissue. The new platform will be used to treat patients at facilities in Europe that are participating in Spectranetics’ initial limited launch. SightRail™ Manual Dilator Sheath, a partner platform, was awarded the CE mark in April and features visual indicators that show bevel orientation and tip alignment, supplementing fluoroscopy as a means to determine position and orientation These new platforms represent Spectranetics’ entry into the mechanical extraction device market, complementing the laser-based technology that established the company’s leading position in cardiac lead extraction. On the heels of completing TightRail’s first in-patient case with Dr. Charles Love, Spectranetics debuted TightRail at the Heart Rhythm Society’s 35th Annual Scientific Sessions in San Francisco earlier this month. Over 200 physicians participated in the “hands-on” Solutions Experience hosted by Spectranetics. TightRail will also headline the CardioStim conference in Nice, France, in June. Donna Ford-Serbu, Senior Vice President, Sales and Marketing for Spectranetics Lead Management business unit, sees the mechanical extraction devices as an exciting addition to the company’s portfolio of lead extraction solutions. “By providing a wider range of clinical solutions, we are responding to a global need for innovative extraction options,” said Ford-Serbu. “Physicians are always looking for ways to serve their patient’s needs – we are committed to providing tools that extend life and ensure physicians are successful at every turn.” There are over seven million implanted cardiac devices globally. Each year, about 750,000 additional patients are implanted with these devices worldwide, translating to 1.5 million leads. It is estimated that in 2014, roughly 400,000 patients will meet indications for a lead extraction procedure. About Spectranetics Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are sold in over 40 countries and are used to treat arterial blockages in the heart and legs, and the removal of pacemaker and defibrillator leads. The Company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart. The Lead Management (LM) product line includes excimer laser sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads. For more information, visit www.spectranetics.com.